A Study of GENEVAX-HIV, a Possible Vaccine

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Study Classification

INTERVENTIONAL

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to see if it is safe to give GENEVAX-HIV, a potential HIV vaccine, to HIV-negative volunteers. The study also compares the effects of GENEVAX-HIV injected into the muscle to the effects of the drug when injected into the skin.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Volunteers receive either intradermal or intramuscular injections of GENEVAX-HIV; humoral and cellular responses are assessed accordingly.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV Infections HIV Seronegativity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

APL 400-003

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Patients must have:

* Good health.
* Ability to understand the basis of HIV transmission and other common sexual and blood-borne infections.
* The following parameters within normal range:
* Hematopoietic:
* total white blood cell, lymphocyte, granulocyte, and platelet count, hemoglobin and hematocrit.
* Renal:
* BUN and creatinine, urinalysis.
* Hepatic:
* total serum bilirubin.
* Endocrine/Metabolic:
* Serum calcium, serum glucose, total serum CPK.
* Immunologic:
* total serum immunoglobulin and absolute CD4 count.
* Hepatitis B and Hepatitis C negative.
* Urinalysis:
* Normal screen with dipstick for esterase and nitrite.

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

* HIV-seropositive status.
* Any positive result for anti-DNA antibodies considered of potential clinical significance as measured by anti-DNA antibody and/or anti-nuclear antibody (ANA) assays.
* Any condition which, in the opinion of the principal investigator, might interfere with completion of the study or evaluation of the results.
* Known hypersensitivity to bupivacaine or any amide-type local anesthetic (such as lidocaine, dibucaine, mepivacaine, and prilocaine) or a history of anaphylaxis or other serious adverse reactions to vaccines.

Concurrent Medication:

Excluded:

Any medication which may affect immune function with the exception of low doses of nonprescription-strength NSAIDS, aspirin, or acetaminophen for acute conditions such as headache or trauma.

Patients with the following prior conditions are excluded:

* HIV-seropositive.
* Known or suspected history of impairment or abnormality in immune functioning.
* Exposure to potentially-infective HIV fluids within the prior 6 months or tested positive for HIV at any time.
* History of any prior disease or therapy which would affect immune function including:
* Prior malignancy, except curatively-treated basal cell or squamous cell carcinoma in situ of the cervix.
* Immunodeficiency or autoimmune disease.
* Acute infection or a recent (within 6 months) history of chronic infection.
* History of serious allergic reaction to any substance requiring hospitalization or emergent medical care (e.g., Stevens-Johnson syndrome, bronchospasm, or hypotension).

Prior Medication:

Excluded:

Cytotoxic chemotherapy that may affect immune function.

Prior Treatment:

Excluded:

* Previous immunization with any experimental vaccines directed against HIV or receipt of any experimental agent within 30 days prior to enrollment.
* Receipt of any blood products or immunoglobulin within 6 months prior to enrollment.
* Exposure to live attenuated vaccines within 60 days of study.
* Radiotherapy that may affect immune function.

Risk Behavior:

Excluded:

* Active drug or alcohol abuse or uncontrolled (unstable) psychiatric disorders which, in the opinion of the investigator, would interfere with study participation.
* Higher- or intermediate-risk sexual behavior (AVEG criteria)

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Merlin Robb

Role: STUDY_CHAIR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Walter Reed Army Institute of Research

Washington D.C., District of Columbia, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

400-003-05

Identifier Type: -

Identifier Source: secondary_id

005